PRECISE-GBM
Cross-source consensus on PRECISE-GBM from 1 sources and 4 claims.
1 sources · 4 claims
Uses
How it works
Risks & contraindications
Highlighted claims
- PRECISE-GBM links pre-operative MRI radiomics with transcriptome-derived immune labels in IDH-wildtype glioblastoma. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- The proposed clinical use of MRI-based immune prediction is trial enrichment before confirmation by tissue analysis. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- PRECISE-GBM assumes that the input tumor is IDH-wildtype glioblastoma and does not distinguish mimicking tumors. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study
- PRECISE-GBM is framed as a proof of concept for non-invasive immune stratification rather than a replacement for tissue-based assessment. — Predictive radiomics for evaluation of cancer immune SignaturE in glioblastoma: the PRECISE-GBM study